Renal Business Today

Renvela

Sanofi Aventis Acquires Genzyme for $20.1 Billion

CAMBRIDGE, Mass.—Sanofi-aventis will acquire Genzyme Corp. for $74 per share in cash, or approximately $20.1 billion, according to a Feb. 16 news release. ...More
February 16, 2011
Posted in News, Business, Government & Regulation
Genzyme 'Encouraged' by Oral-Drug Delay in Bundle

CAMBRIDGE, Mass.—In a July 27 news release, Genzyme Corp. said it was “encouraged” by the Centers for Medicare & Medicaid Services’ (CMS) decision not to immediately include oral medications without IV equivalents in the newly released dialysis bundled payment system. ...More
July 27, 2010
Posted in News, Business
Genzyme Sues Watson Over Generic Renvela Application

MORRISTOWN, N.J.—Watson Pharmaceuticals Inc. said July 12 that it has submitted an application to the U.S. Food and Drug Administration to approve a generic form of Genzyme’s phosphate binder Renvela. ...More
July 13, 2010
Posted in News, Government & Regulation
Generic Renvela Maker Files for FDA Approval

Generic drug makers have been going after phosphate binders for short while now; however, it could reach a fever pitch after Genzyme sued Impax Laboratories on July 1 for trying to create a generic form of Renvela. ...More
July 7, 2010
Posted in Blog, Clinical & Pharma, Government & Regulation
Genzyme Ends Development of Renvela Successor

CAMBRIDGE, Mass.—Genzyme Corp. said Nov. 18 that it has ended the development of a new phosphate binder for dialysis patients because the new drug did not work much better than its existing drug Renvela. ...More
November 18, 2009
Posted in News, Business, Clinical & Pharma
FDA Approves Powder Form of Genzyme’s Renvela

CAMBRIDGE, Mass.—The U.S. Food and Drug Administration approved on August 12 a powder form of Genzyme’s phosphate binder Renvela. ...More
September 2, 2009
Posted in News, Business, Clinical & Pharma
Europe Approves Genzyme’s Renvela for CKD Patients

CAMBRIDGE, Mass.—The European Commission has approved Genzyme’s phosphorus binder Renvela for use in chronic kidney disease patients. ...More
June 12, 2009
Posted in News, Business, Clinical & Pharma
Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More
April 28, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
Genzyme Transitions Renagel Users to Renvela

Earlier this year, Cambridge, Mass.-based Genzyme Corp. announced that it’s working with physicians to transition all U.S. patients on the phosphate binder Renagel to Renvela by Sept. 30. ...More
February 26, 2009
Posted in Articles, Business, Clinical & Pharma, Government & Regulation
Genzyme Transitioning U.S. Renagel Market to Renvela

CAMBRIDGE, Mass.—Genzyme Corp. said Jan. 14 that it’s working with physicians to transition all U.S. patients on the phosphate binder Renagel to Renvela by Sept. 30. ...More
January 14, 2009
Posted in News, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Renvela

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail